Advertisement


Mary-Ellen Taplin, MD, FASCO, on High-Risk Localized or Locally Advanced Prostate Cancer: PROTEUS Trial

ASCO 2026

Advertisement

Mary-Ellen Taplin, MD, FASCO, of Dana-Farber Cancer Institute, presents the final analysis of the phase III PROTEUS study, which looked at perioperative (neoadjuvant and adjuvant) apalutamide plus androgen-deprivation therapy (ADT) vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer (Abstract LBA1).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Prostate cancer patients who are diagnosed with localized high-risk disease have high rates of relapse after standard-of-care treatment options of prostatectomy or radiation combined with androgen deprivation therapy. We designed the PROTEUS trial to test the hypothesis that 6 months of apalutamide combined with androgen deprivation therapy, given both before and after prostatectomy and compared to a control arm of placebo and androgen deprivation therapy, would improve two coprimary endpoints. These coprimary endpoints were major pathologic response, which was measured by either a complete response of tumor in the prostate or having a minimal amount of residual disease, less than 5 mm of tumor. And the second coprimary endpoint was metastasis-free survival. So PROTEUS was an international trial. It was done in 18 countries. A total of 2,109 patients were randomly assigned to these two cohorts and then followed, and the median time of follow-up was just over 5 years. When the data read out, what the data showed was that for the apalutamide ADT treatment, there was a ninefold improvement in the primary endpoint of a major pathologic response. This was measured by having no tumor or less than 5 mm of tumor. And there was an exploratory endpoint called residual cancer burden that also measures tumor cellularity and size, and that was 30% for apalutamide androgen deprivation compared with 11% for placebo androgen deprivation. So all of these pathology results show that apalutamide and ADT is killing more cancer cells in the prostate. The other coprimary endpoint is metastasis-free survival, and that was measured by PSMA PET imaging or conventional imaging, and that endpoint showed a 20% improvement for the apalutamide ADT. And in addition, if the MFS was measured by investigator-assessed MFS as opposed to the blinded central reviewer, there was a 24% improvement in MFS. These primary endpoints were supported by positive results in the secondary endpoints, a measure called event-free survival, which is recurrence of prostate cancer by any measure, PSA, local recurrence, any of the imaging that showed it’s also a significant benefit for apalutamide and ADT, with a 29% reduction for the apalutamide compared with the ADT alone. And then another secondary endpoint, which is called time to first subsequent therapy, was markedly positive, with almost a 3-year difference for the patients in the apalutamide ADT cohort needing another treatment. The known side effects of apalutamide, there was an incidence of rash. The rash was generally well controlled with standard algorithms that we use to treat rash that is seen with apalutamide and other stages of prostate cancer. So very excited about these primary and secondary endpoints. The exploratory endpoints support the other endpoints, and we’re very excited about the future work. There was a substudy in which 400 men were assigned to just going to prostatectomy or compared with the PROTEUS regimen, the 6 months of apalutamide and ADT before and after prostatectomy. So that study will read out later this year. We’re excited to see we are hypothesizing even a bigger difference, and the biomarker data will just be incredible. It’s 2,109 men that we will be able to look at metrics of favorable response versus resistance and be able to use generated hypotheses from PROTEUS to plan subsequent neoadjuvant and adjuvant work to improve the cure rates even more.

Related Videos

Lymphoma
Leukemia

Supriya Gupta, MD, on Investigational CAR T-Cell Therapy in Relapsed or Refractory NHL and CLL

Supriya Gupta, MD, of the University of Minnesota, presents data on azercabtagene zapreleucel, an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T-cell therapy, in combination with low-dose interleukin-2 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) (Abstract 7012). 

Lung Cancer

Laura Alder, MD, on New Data on Combination Therapy, Immunotherapy, and ADCs in Small Cell Lung Cancer

Laura Alder, MD, of Duke University Medical Center, highlights emerging data discussed in the meeting’s oral abstract session on small cell lung cancer, including increased toxicity without efficacy benefit from concurrent chemoradiation and immunotherapy, the intracranial activity of tarlatamab-dlle, and early data for a SEZ6-targeting antibody-drug conjugate. 

Pancreatic Cancer

Shubham Pant, MD, MBBS, on Novel RAS-Targeting Therapy Daraxonrasib Doubles Overall Survival in Metastatic Pancreatic Cancer

Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median overall survival compared with standard chemotherapy in pretreated metastatic pancreatic cancer (Abstract LBA5).  

Gastroesophageal Cancer

Elena Elimova, MD, on PD-L1 Subgroup Analysis From HERIZON-GEA-01

Elena Elimova, MD, Princess Margaret Cancer Centre, discusses the efficacy in PD-L1 subgroups of zanidatamab plus chemotherapy with or without tislelizumab as a first-line regimen for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (Abstract 4010).

Lung Cancer

Tony S.K. Mok, MD, FRCPC, FASCO, on Advanced ALK-Positive NSCLC: 7-Year Update From the CROWN Trial

Tony S.K. Mok, MD, FRCPC, FASCO, of the Chinese University of Hong Kong, presents long-term findings from the CROWN trial, which evaluated lorlatinib vs crizotinib in patients with advanced ALK-positive non–small cell lung cancer (NSCLC). At 5 years, median progression-free survival was not reached with lorlatinib in this population, representing the longest progression-free survival ever reported in advanced NSCLC (Abstract 8502). 

Advertisement

Advertisement




Advertisement